{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T15:29:58Z","timestamp":1700407798436},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T00:00:00Z","timestamp":1464048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00063-016-0153-0","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T13:16:27Z","timestamp":1464095787000},"page":"145-148","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Wenn der Patient sauer aber nicht s\u00fc\u00df ist"],"prefix":"10.1007","volume":"112","author":[{"given":"R.","family":"Valek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Von der Mark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,24]]},"reference":[{"key":"153_CR1","unstructured":"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm446845.htm\n                        \n                    . Zugegriffen: 10.12.2015"},{"key":"153_CR2","unstructured":"http:\/\/www.deutsche-diabetes-gesellschaft.de\/fileadmin\/Redakteur\/Stellungnahmen\/2015\/DDG-Stellungnahme-Ketoazidosen.pdf\n                        \n                    . Zugegriffen: 10.12.2015"},{"issue":"7","key":"153_CR3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","volume":"32","author":"AE Kitabchi","year":"2009","unstructured":"Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32(7):1335\u20131343","journal-title":"Diabetes Care"},{"issue":"9","key":"153_CR4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38(9):1687\u20131693","journal-title":"Diabetes Care"},{"issue":"8","key":"153_CR5","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI (2015) SGLT2 inhibitors may predispose to ketoacidosis. J\u00a0Clin Endocrinol Metab 100(8):2849\u20132852","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"153_CR6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B et al (2015) EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373(22):2117\u20132128","journal-title":"N Engl J Med"},{"key":"153_CR7","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors__20\/Procedure_started\/WC500187926.pdf\n                        \n                    . Zugegriffen: 10.12.2015"},{"key":"153_CR8","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors__20\/Procedure_started\/WC500187927.pdf\n                        \n                    . Zugegriffen: 10.12.2015"},{"key":"153_CR9","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors__20\/Procedure_started\/WC500187928.pdf\n                        \n                    . Zugegriffen: 10.12.2015"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-016-0153-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-016-0153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-016-0153-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-016-0153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T02:29:09Z","timestamp":1558578549000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-016-0153-0"}},"subtitle":["Die euglyk\u00e4mische diabetische Ketoacidose unter SGLT2-Inhibitoren"],"short-title":[],"issued":{"date-parts":[[2016,5,24]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["153"],"URL":"https:\/\/doi.org\/10.1007\/s00063-016-0153-0","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,24]]}}}